Health

2024-04-05 10:00:03

Every Friday, we deal with a women’s health topic in a practical way. This week we are talking regarding musculoskeletal disorders. This pain manifests itself as discomfort in movements and is localized at or around joints such as the wrist, elbow or even the knee.

Skeletal-muscular pain manifests itself as discomfort in movements. © Getty Images – PeopleImages

A rheumatologist answers questions from listeners:

Music programming :

► Singuila feat. Youssoupha – Rossignol

► Faith – Wonderful life.

NewsletterReceive all the international news directly in your inbox

I subscribe

Continue reading on the same themes:

1712472301
#Womens #questions #musculoskeletal #pain

#Identifying #relationship #dental #hygiene #deadly #cancer
2024-04-07 05:20:05

2024-04-07 04:10:00

Smoking, high blood pressure, elevated cholesterol levels, atrial fibrillation, lack of exercise – all of these are traditionally considered risk factors for a stroke. A new study from the University of Colorado shows that non-traditional risk factors are likely to play an important role in the development of a stroke, especially at younger ages.

According to the researchers, these non-traditional risk factors include blood clotting disorders, kidney failure, autoimmune and cancer diseases, and especially migraines. These are “significantly associated with the development of a stroke” in people aged 18 to 44, writes the “Deutsche Ärzteblatt” regarding the study.

Traditional vs. non-traditional risk factors

The study included data from a health insurance database of 2,618 people who had a stroke; these were compared with 7,827 data sets from people who had not suffered a stroke. It was found that non-traditional risk factors were predominantly strongly associated with strokes, particularly in people under 35 years of age. Migraine was the most important non-traditional stroke risk factor among 18 to 24 year olds, accounting for 20.1 percent of men and 34.5 percent of women.

“The younger patients are at the time of the stroke, the higher the likelihood that the stroke is due to a non-traditional risk factor,” says lead author Michelle Leppert from the University of Colorado. The aim now is to research what mechanisms underlie these non-traditional risk factors.

From the age of 45, the importance of traditional risk factors increases. These are associated with strokes in 32 percent of men and 38.9 percent of women. The non-traditional ones accounted for 19.4 and 27.9 percent.

1712466070
#Migraine #risk #factor #stroke #younger #ages

2024-04-06 17:15:00

Bristol Myers Squibb said Saturday that data from late-stage trials of its experimental schizophrenia drug showed it reduced symptoms of the disorder without the common side effect of weight gain associated with other antipsychotics.

The drugmaker gained access to the drug, called KarXT, through its $14 billion acquisition of Karuna Therapeutics last year. The drug’s long-term data confirmed the results of previous short-term studies, the company said.

In a one-year follow-up, the drug helped curb symptoms such as delusions and reduced speech ability by greater than or equal to 30% in over 75% of patients, as measured on a scale measuring the disease.

“Current antipsychotic treatments are associated with a range of adverse effects, including adverse metabolic profiles, weight gain… and there remains a need for more effective treatments,” said Roland Chen, SVP, Global Drug Development for Immunology, Neuroscience and Cardiovascular Development at Bristol Myers.

The data shows that KarXT reduced weight by an average of 2.56 kilograms following 52 weeks. The majority of participants, 65.1%, experienced weight loss over the course of the study, with 17.6% of them experiencing a loss in body weight greater than or equal to 7%.

Overall, 14.9% of patients discontinued the study due to treatment-related adverse events. The most common adverse events were nausea and vomiting, most of which were mild and transient, the company said.

KarXT is expected to drive sales into the late 2020s and into the next decade, at a time when two of Bristol Myers’ flagship drugs, blood cancer therapy Revlimid and blood thinner Eliquis, face generic competition . (Reporting by Sneha SK in Bengaluru; Editing by Shilpi Majumdar)

1712458564
#Bristol #Myers #schizophrenia #drug #reduces #symptoms #weight #gain #latestage #trials #April #p.m